EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut microbiota shaping fatty liver disease progression

Martyna Wysokińska iD, Marta Mysza iD, Aleksandra E Uryga iD, Aleksandra A Kołodziejczyk iD

Life Science Alliance · 2027

DOI: 10.26508/lsa.202603756 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life Science Alliance, 2027. Verfasst von Martyna Wysokińska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Fatty Liver. Die Arbeit nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency, European Molecular Biology Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut–liver axis is an important regulator of homeostasis, and its dysregulation has been implicated in the pathogenesis of metabolic dysfunction–associated steatotic liver disease (MASLD). In this review, we summarize current knowledge on both compositional alterations of the gut microbiome in MASLD and the functional consequences of these changes. We first discuss changes across major microbial domains, including bacteria, archaea, eukaryota, and bacteriophages, and then focus on microbiota-derived metabolites, such as short-chain fatty acids, trimethylamine and its derivative trimethylamine N-oxide, tryptophan-derived indoles, secondary bile acids, and other bioactive compounds. Their complex impacts on intestinal barrier integrity, inflammation, lipid and glucose metabolism, and immune and hormonal signaling in the liver are highlighted. We further examine mechanisms involving the translocation of microbial products and the modulation of nuclear and membrane receptors. Finally, we outline current challenges and knowledge gaps that need to be addressed to better understand the role of the gut microbiota in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeFatty LiverHumansAnimalsDisease ProgressionLiverIntestinal Barrier FunctionMethylaminesLipid MetabolismBacteriaBile Acids and SaltsFatty Acids, Volatile

Substanzen

MethylaminesBile Acids and SaltsFatty Acids, Volatile

Autor:innen und Institutionen

  • Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland.
  • Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology, Warsaw, Poland akolodziejczyk@iimcb.gov.pl.

ORCID-Profile: Martyna Wysokińska, Marta Mysza, Aleksandra E Uryga, Aleksandra A Kołodziejczyk

Förderung

  • Medical Research Agency
  • European Molecular Biology Organization

Zitieren

APA

Wysokińska, M., Mysza, M., Uryga, A. E., & Kołodziejczyk, A. A. (2027). Gut microbiota shaping fatty liver disease progression. Life Science Alliance. https://doi.org/10.26508/lsa.202603756

Vancouver

Wysokińska M, Mysza M, Uryga AE, Kołodziejczyk AA. Gut microbiota shaping fatty liver disease progression. Life Science Alliance. 2027. doi:10.26508/lsa.202603756

BibTeX
@article{Wysokiska2027,
  author = {Wysokińska, Martyna and Mysza, Marta and Uryga, Aleksandra E and Kołodziejczyk, Aleksandra A},
  title = {Gut microbiota shaping fatty liver disease progression},
  journal = {Life Science Alliance},
  year = {2027},
  doi = {10.26508/lsa.202603756}
}
Kostenlos starten →